tldrdailynews.com logo

Breakthrough drug targets ‘undruggable’ cancer, doubles survival in pancreatic cancer

1 min read
Source: Nature
Breakthrough drug targets ‘undruggable’ cancer, doubles survival in pancreatic cancer
Photo: Nature
TL;DR

A large trial shows the experimental drug daraxonrasib inhibits all three RAS family proteins and nearly doubles survival in advanced pancreatic cancer (13.2 months vs 6.7 with chemotherapy), marking a breakthrough against previously undruggable targets and highlighting prospects for combination therapies and broader use in hard-to-treat tumors.

Topics:top-newsscience#clinical-trial#daraxonrasib#pancreatic-cancer#ras#science#undruggable
Share this article
  1. Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments  Nature
  2. Experimental pill promises new hope for deadly pancreatic cancer  AP News
  3. This new drug could change how we treat one of the deadliest cancers  PBS
  4. Daily pill can double survival time for world’s deadliest cancer, trial shows | Pancreas cancer  The Guardian
  5. Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO 2026: A Game-Changer  Oncology News Central

Want the full story? Read the original reporting

Read on Nature